Marti Technologies Inc. (MRT)
AMEX AMEX Primary 
Marti Is Highly Risky, Financially And Operationally
Marti Is Highly Risky, Financially And Operationally
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
Marti: A Potential Early-Stage Opportunity Has Emerged
Marti Technologies, Inc. (MRT) offers hyper-growth exposure to Turkey's e-hailing and mobility market, combining ride-hailing, delivery, and self-use fleet services. MRT's 2025 revenue grew 110.3% year-over-year, with adjusted EBITDA margin improving from -104% to -31%, signaling early operating leverage and monetization progress. Management guides for 2026 revenue of $70 million and positive adjusted EBITDA, supported by rapid ride growth and SG&A stabilization.
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Monte Rosa Therapeutics delivered strong interim phase 1 results for MRT-8102, showing deep NEK7 degradation and competitive hsCRP reductions in cardiovascular risk patients. The results further validate its molecular glue degrader platform and position MRT-8102 as an upstream approach versus IL-1/IL-6 targeting biologics. Results of MRT-2359 in heavily pretreated patients with metastatic castration-resistant prostate cancer are inconclusive.
Monte Rosa: Looking Mispriced After Big Pharma Validation
Monte Rosa Therapeutics (GLUE) is transitioning from an oncology focus to a next-gen immunology & inflammation (I&I) platform, with significant pharma partnerships. GLUE's pipeline features MRT-6160 (VAV1 degrader, partnered with Novartis), MRT-8102 (NEK7 degrader), and MRT-2359 (oncology), offering both I&I and oncology upside. Strong financial position with ~$400M cash, multiple lucrative deals with Novartis and Roche, and a cash runway through 2028 reduce near-term dilution risk.
Marti Technologies, Inc. (MRT) Q2 2025 Earnings Call Transcript
Marti Technologies, Inc. (NYSE:MRT ) Q2 2025 Earnings Call September 22, 2025 8:30 AM EDT Company Participants Oguz Oktem - Founder, CEO & Chairman Cankut Durgun Conference Call Participants Theodore O'Neill - Litchfield Hills Research, LLC John Halpert - Cantor Fitzgerald & Co., Research Division Rohit Kulkarni - ROTH Capital Partners, LLC, Research Division Yanfang Jiang - The Benchmark Company, LLC, Research Division Siddharth Havaldar Presentation Operator Hello, everyone, and thank you for joining us for Marti Technologies First Half 2025 Conference Call. Before we begin, I'd like to mention that today's earnings release and slide presentation are available on Marti's Investor Relations website at ir.marti.tech, where you will also find links to our SEC filings, along with other information about Marti.
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC
Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials targeting inflammatory and cardio-immunology disorders, with key data expected in H1 2026. Strong financial position with $295.5M in cash as of June 2025, supported by multiple big pharma collaborations, funding operations into 2028.
Marti Technologies, Inc. (MRT) Q4 2024 Earnings Call Transcript
Marti Technologies, Inc. (NYSE:MRT ) Q4 2024 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Cankut Durgun - Founder and President Oguz Alper Oktem - Co-Founder and CEO Conference Call Participants Rohit Kulkarni - ROTH Capital Poe Fratt - Alliance Global Partners Theodore O'Neil - Litchfield Hills Research Siddharth Havaldar - Crescent Enterprises Operator Greetings, and welcome to Marti Technologies, Inc. Full Year 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode.
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, with key data expected in 2025.
Marti Technologies: A Lofty But Realistic Guidance To Positive Free Cash Flow In 2025
Marti Technologies, Inc. is a "Strong Buy" in Turkey's ride-hailing market, trading at $3.54 per share with a $207 million market cap. Experienced founders, leading market position, and recent monetization of ride-hailing services highlight Marti's competitive advantages and growth potential. Financial outlook for 2025 shows significant revenue growth, positive EBITDA, and free cash flow, driven by expanded services and operational efficiencies.
Unlocking Marti's $8 Billion Opportunity
Marti surpassed 1.6 million riders and 255,000 drivers, achieving 15% ride growth in six months. Estimated at $9–$12 billion TAM, with Marti positioned to capture a $2 billion revenue potential. Marti's driver subscription model implies a 10% effective take rate, offering $800 million initial revenue potential.
